Phone: 614/488-2118
Fax: 614/488-2647
1335 Dublin Rd., Suite 124A
Columbus, OH 43215
Member Sign in
HOME
MEMBERS
CANCER RESOURCES
ABOUT
EVENTS
EMPLOYMENT
CONTACT
Protocol Database
User Profile
Index of Forms
Ohio Partners for Cancer Control
Consortium Members
Investigators
Community Based Research Staff
NCORP Videos
Our Team
Donate
HOME
MEMBERS
Protocol Database
User Profile
Index of Forms
CANCER RESOURCES
Ohio Partners for Cancer Control
ABOUT
Consortium Members
Investigators
Community Based Research Staff
NCORP Videos
EVENTS
EMPLOYMENT
CONTACT
Our Team
Donate
Enter your search term
Protocol Categories
View All Protocols
Brain
Breast
CA Control
CCDR
Gastrointestinal
Genitourinary
GYN
Head and Neck
Hematology
Lung
Lymphoma
Melanoma / Skin-Other
Multiple Disease Sites
Observational
RT
Sarcoma
Unknown Primary
DCP
ComboMATCH
Lung
Alliance A081801 ALCHEMIST chemo-IO
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
ECOG EA5182
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
ECOG EA5221
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
ECOG EAQ222CD
Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
ECOG EAY191 (ComboMatch)
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
NRG LU007
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
NRG LU008
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
OSU OSU 2017C0048: BLCIO
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients with Stage IV Non-Small Cell Lung Cancer (BLCIO)
SWOG LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG LUNGMAP Subprotocol S1900G
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
URCC 22063
Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
Wake Forest WF 2304-A172401 (COSMIC)
Complementary Options for Symptom Management In Cancer (COSMIC)